[1]. Hussain, Y.S., Hookham, J.C., Allahabadia, A., Balasubramanian, S.P.,
Epidemiology, management and outcomes of graves’ disease—real life data.
Endocrine,
2017, 56(3), 568-578.
[3]. Pokhrel B, Bhusal K.
Graves disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing;
2023.
[4]. Stasiak, M., Stasiak, B., Zawadzka-Starczewska, K., Lewiński, A.,
Significance of hla in graves’ disease and graves’ orbitopathy in asian and caucasian populations–a systematic review.
Frontiers in Immunology,
2023, 14, 1256922.
[5]. Bartalena, L., Tanda, M.L.,
Current concepts regarding graves’ orbitopathy.
Journal of Internal Medicine,
2022, 292(5), 692-716.
[6]. Cao, Y., Zhao, X., You, R., Zhang, Y., Qu, C., Huang, Y., Yu, Y., Gong, Y., Cong, T., Zhao, E.,
Cd11c+ b cells participate in the pathogenesis of graves’ disease by secreting thyroid autoantibodies and cytokines.
Frontiers in Immunology,
2022, 13, 836347.
[7]. Diana, T., Olivo, P.D., Kahaly, G.J.,
Thyrotropin receptor blocking antibodies.
Hormone and Metabolic Research,
2018, 50(12), 853-862.
[8]. Kahaly, G.J., Diana, T.,
Tsh receptor antibody functionality and nomenclature.
Frontiers in Endocrinology,
2017, 8, 28.
[9]. Pirahanchi Y, Toro F, Jialal I
. Physiology, thyroid stimulating hormone. StatPearls. Treasure Island (FL)
2023.
-Starczewska, K., Tymoniuk, B., Stasiak, B., Lewiński, A., Stasiak, M.,
Actual associations between hla haplotype and graves’ disease development.
Journal of Clinical Medicine,
2022, 11(9), 2492.
[11]. Li, Y., Yao, Y., Yang, M., Shi, L., Li, X., Yang, Y., Zhang, Y., Xiao, C.,
Association between hla-b* 46 allele and graves disease in asian populations: A meta-analysis.
International Journal of Medical Sciences,
2013, 10(2), 164.
[12]. Huang, X., Liu, G., Mei, S., Cai, J., Rao, J., Tang, M., Zhu, T., Chen, W., Peng, S., Wang, Y.,
Human leucocyte antigen alleles confer susceptibility and progression to graves’ ophthalmopathy in a southern chinese population.
British Journal of Ophthalmology,
2021, 105(10), 1462-1468.
[13]. Cheung, Y.K., Cheng, S.H., Chan, E.J., Lo, S.V., Ng, M.H., Kwan, P.,
Hla‐b alleles associated with severe cutaneous reactions to antiepileptic drugs in h an c hinese.
Epilepsia,
2013, 54(7), 1307-1314.
[14]. Hansen, M., Cheever, A., Weber, K.S., O’Neill, K.L.,
Characterizing the interplay of lymphocytes in graves’ disease.
International Journal of Molecular Sciences,
2023, 24(7), 6835.
[15]. Hammad, H., Lambrecht, B.N.,
The basic immunology of asthma.
Cell,
2021, 184(6), 1469-1485.
[17]. Bogović Crnčić, T., Girotto, N., Ilić Tomaš, M., Krištofić, I., Klobučar, S., Batičić, L., Ćurko-Cofek, B., Sotošek, V.,
Innate immunity in autoimmune thyroid disease during pregnancy.
International Journal of Molecular Sciences,
2023, 24(20), 15442.
[18]. Yamakawa, H., Kato, T.S., Noh, J.Y., Yuasa, S., Kawamura, A., Fukuda, K., Aizawa, Y.,
Thyroid hormone plays an important role in cardiac function: From bench to bedside.
Frontiers in physiology,
2021, 12, 606931.
[20]. Van Le, C., Linh, P.N.T., Thi, X.N., Vo, T.T.,
Pretibial myxedema in grave's disease: A case report and treatment review of the literature.
Clinical Case Reports,
2024, 12(2), e8478.
[21]. Abdi, H., Amouzegar, A., Azizi, F.,
Antithyroid drugs.
Iranian Journal of Pharmaceutical Research: IJPR,
2019, 18(Suppl1), 1.
[22]. Awosika AO, Singh G, Correa R.
Methimazole. InStatPearls,
2023.
[23]. Kim, H.J.,
Long-term management of graves disease: A narrative review.
Journal of Yeungnam Medical Science,
2023, 40(1), 12-22.
[24]. DeGroot LJ.
Diagnosis and treatment of Graves' disease. Endotext. South Dartmouth (MA),
2016.
[25]. Padda IS, Nguyen M.
Radioactive iodine therapy. Treasure Island (FL):
2023.
[26]. Ponto, K.A., Zang, S., Kahaly, G.J.,
The tale of radioiodine and graves' orbitopathy.
Thyroid,
2010, 20(7), 785-793.
[28]. Biello A,
Kinberg EC, Menon G, Wirtz ED. Thyroidectomy. StatPearls. Treasure Island (FL),
2024.
[30]. Ugradar, S., Malkhasyan, E., Douglas, R.S.,
Teprotumumab for the treatment of thyroid eye disease.
Endocrine Reviews,
2024, 45(6), 843-857.
[31]. Salvi, M., Vannucchi, G., Currò, N., Campi, I., Covelli, D., Dazzi, D., Simonetta, S., Guastella, C., Pignataro, L., Avignone, S.,
Efficacy of b-cell targeted therapy with rituximab in patients with active moderate to severe graves' orbitopathy: A randomized controlled study.
The Journal of Clinical Endocrinology & Metabolism,
2015, 100(2), 422-431.
[32]. Lane, L.C., Cheetham, T.D., Perros, P., Pearce, S.H.,
New therapeutic horizons for graves’ hyperthyroidism.
Endocrine Reviews,
2020, 41(6), 873-884.
[33]. Furmaniak, J., Sanders, J., Sanders, P., Li, Y., Rees Smith, B.,
Tsh receptor specific monoclonal autoantibody k1‐70tm targeting of the tsh receptor in subjects with graves' disease and graves' orbitopathy—results from a phase i clinical trial.
Clinical endocrinology,
2022, 96(6), 878-887.
[34]. Mozzi, A., Pontremoli, C., Sironi, M.,
Genetic susceptibility to infectious diseases: Current status and future perspectives from genome-wide approaches.
Infection, genetics and evolution,
2018, 66, 286-307.
[36]. Smith, T.J., Hegedüs, L.,
Graves’ disease.
New England Journal of Medicine,
2016, 375(16), 1552-1565.
[37]. Rincon-Arevalo, H., Wiedemann, A., Stefanski, A.-L., Lettau, M., Szelinski, F., Fuchs, S., Frei, A.P., Steinberg, M., Kam-Thong, T., Hatje, K.,
Deep phenotyping of cd11c+ b cells in systemic autoimmunity and controls.
Frontiers in Immunology,
2021, 12, 635615.
[38]. Huber, A., Menconi, F., Corathers, S., Jacobson, E.M., Tomer, Y.,
Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: From epidemiology to mechanisms.
Endocrine Reviews,
2008, 29(6), 697-725.
[39]. Kahaly, G.J.,
Immunotherapies for thyroid eye disease.
Current Opinion in Endocrinology, Diabetes and Obesity,
2019, 26(5), 250-255.
[40]. Ross, D.S., Burch, H.B., Cooper, D.S., Greenlee, M.C., Laurberg, P., Maia, A.L., Rivkees, S.A., Samuels, M., Sosa, J.A., Stan, M.N.,
2016 american thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis.
Thyroid,
2016, 26(10), 1343-1421.
[41]. Abraham, P., Avenell, A., McGeoch, S.C., Clark, L.F., Bevan, J.S.,
Antithyroid drug regimen for treating graves' hyperthyroidism.
Cochrane Database of Systematic Reviews,
2010, (1).
[42]. Cooper, D.S.,
Antithyroid drugs.
New England Journal of Medicine,
2005, 352(9), 905-917.
[43]. Association, A.T., Hyperthyroidism, A.A.o.C.E.T.o., Thyrotoxicosis, O.C.o., Bahn, R.S., Burch, H.B., Cooper, D.S., Garber, J.R., Greenlee, M.C., Klein, I., Laurberg, P., McDougall, I.R., Montori, V.M.,
Hyperthyroidism and other causes of thyrotoxicosis: Management guidelines of the american thyroid association and american association of clinical endocrinologists.
Thyroid,
2011, 21(6), 593-646.
[44]. Kim MY, Kim JH, Cho MH, Choi YH, Kim SH, Im YJ, Park K, Kang HG, Chae JH, Cheong HI.
Urological problems in patients with Menkes disease.
J. Korean Med. Sci.
2019 ;34:e4.
[45]. Razavi CR, Tufano RP, Russell JO.
Completion thyroidectomy: what are the risks of waiting? Gland Surg.
2019; 8(Suppl 2): S112-S120.
